S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:OMCL

Omnicell (OMCL) Stock Forecast, Price & News

$49.82
-1.24 (-2.43%)
(As of 05:12 PM ET)
Compare
Today's Range
$49.52
$52.08
50-Day Range
$51.06
$72.37
52-Week Range
$46.11
$91.99
Volume
488,606 shs
Average Volume
492,844 shs
Market Capitalization
$2.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.75

Omnicell MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
38.3% Upside
$68.75 Price Target
Short Interest
Healthy
4.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.27mentions of Omnicell in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
50.68%
From $0.73 to $1.10 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

249th out of 968 stocks

Electronic Computers Industry

4th out of 5 stocks


OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

OMCL Price History

OMCL Stock News Headlines

Omnicell, Inc.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
Craig-Hallum Sticks to Their Buy Rating for Omnicell (OMCL)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Q2 2023 Omnicell Inc Earnings Call
Omnicell Announces Second Quarter 2023 Results
4 Analysts Have This to Say About Omnicell
Omnicell Inc.
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
8/01/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
4,230
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$68.75
High Stock Price Forecast
$88.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+38.0%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$5.65 million
Pretax Margin
-2.20%

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Cash Flow
$3.88 per share
Book Value
$25.52 per share

Miscellaneous

Free Float
43,964,000
Market Cap
$2.25 billion
Optionable
Optionable
Beta
0.84

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Randall A. LippsMr. Randall A. Lipps (Age 66)
    Founder, Exec. Chairman, Pres & CEO
    Comp: $1.2M
  • Mr. Corey J. Manley
    Exec. VP and Chief Legal & Admin. Officer
  • Mr. Nchacha Etta (Age 52)
    Exec. VP & CFO
  • Ms. Minoo Mortazavi
    Sr. VP of Global Operations
  • Mr. Joseph Brian SpearsMr. Joseph Brian Spears (Age 63)
    Sr. VP, Chief Accounting Officer & Corp. Controller
  • Mr. Virad Gupta
    Sr. VP & CTO
  • Mr. Giri Chodavarapu
    Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth
    Sr. VP of Investor Relations
  • Mr. Maximo Rocha
    Sr. VP & Chief People Officer
  • Mr. Jorge R. Taborga (Age 64)
    Exec. VP of Engineering & Integration Management Officer













OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2023?

7 brokerages have issued 12-month price targets for Omnicell's stock. Their OMCL share price forecasts range from $54.00 to $88.00. On average, they expect the company's stock price to reach $68.75 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2023?

Omnicell's stock was trading at $50.42 at the start of the year. Since then, OMCL shares have decreased by 1.2% and is now trading at $49.82.
View the best growth stocks for 2023 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its earnings results on Tuesday, August, 1st. The company reported $0.29 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.30. The firm earned $298.97 million during the quarter, compared to analysts' expectations of $285.25 million. Omnicell had a positive trailing twelve-month return on equity of 4.47% and a negative net margin of 1.88%.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY23 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $1.75-$2.00 for the period, compared to the consensus estimate of $1.68. The company issued revenue guidance of $1.16-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (2.97%), Conestoga Capital Advisors LLC (2.48%), Champlain Investment Partners LLC (2.23%), Geneva Capital Management LLC (2.22%), Geode Capital Management LLC (2.06%) and Dimensional Fund Advisors LP (1.88%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $49.82.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $2.25 billion and generates $1.24 billion in revenue each year. The company earns $5.65 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Omnicell have?

The company employs 4,230 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (877) 415-9990, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -